Q3 2024 Holdings
Filed 2024-11-14 | 36 holdings | $1.2B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| CG Oncology, Inc.(CGON) | COMM | 156944100 | $138.5M | 3,670,206 | 11.7% |
| Dyne Therapeutics, Inc(DYN) | COMM | 26818M108 | $95.2M | 2,650,150 | 8.1% |
| Cogent Biosciences Inc(COGT) | COMM | 19240Q201 | $75.2M | 6,964,375 | 6.4% |
| Abivax SA(ABVX) | ADRS | 00370M103 | $69.8M | 6,056,596 | 5.9% |
| Edgewise Therapeutics, Inc.(EWTX) | COMM | 28036F105 | $56.4M | 2,112,984 | 4.8% |
| Silence Therapeutics PLC(SLN) | ADRS | 82686Q101 | $55.2M | 3,033,560 | 4.7% |
| Savara Inc.(SVRA) | COMM | 805111101 | $52.4M | 12,362,205 | 4.4% |
| Keros Therapeutics, Inc.(KROS) | COMM | 492327101 | $51.1M | 879,344 | 4.3% |
| Xencor Inc(XNCR) | COMM | 98401F105 | $48.8M | 2,427,138 | 4.1% |
| Tyra Biosciences Inc(TYRA) | COMM | 90240B106 | $46.8M | 1,989,103 | 4.0% |
| Structure Therapeutics Inc(GPCR) | ADRS | 86366E106 | $46.7M | 1,063,000 | 4.0% |
| Ocular Therapeutix, Inc.(OCUL) | COMM | 67576A100 | $46.3M | 5,319,148 | 3.9% |
| Centessa Pharmaceuticals PLC(CNTA) | COMM | 152309100 | $46.2M | 2,890,816 | 3.9% |
| Tourmaline BIO Inc(TRML) | COMM | 89157D105 | $38.0M | 1,477,593 | 3.2% |
| Third Harmonic BIO Inc(THRD) | COMM | 88427A107 | $32.7M | 2,415,000 | 2.8% |
| Astria Therapeutics, Inc.(CATBUSD) | COMM | 04635X102 | $30.4M | 2,761,861 | 2.6% |
| Mineralys Therapeutics, Inc.(MLYS) | COMM | 603170101 | $29.9M | 2,470,265 | 2.5% |
| Kura Oncology Inc(KURA) | COMM | 50127T109 | $27.8M | 1,423,642 | 2.4% |
| Soleno Therapeutivs, Inc.(SLNO) | COMM | 834203309 | $27.8M | 550,000 | 2.4% |
| Compass Pathways PLC(CMPS) | ADRS | 20451W101 | $24.3M | 3,858,000 | 2.1% |
| Disc Medicine, Inc.(IRON) | COMM | 254604101 | $23.9M | 486,957 | 2.0% |
| Fulcrum Therapeutics Inc(FULC) | COMM | 359616109 | $18.7M | 5,250,000 | 1.6% |
| MBX Biosciences Inc(MBX) | COMM | 55287L101 | $16.9M | 650,000 | 1.4% |
| Amylyx Pharmaceuticals Inc(AMLX) | COMM | 03237H101 | $15.0M | 4,643,812 | 1.3% |
| Adverum Biotechnologies, Inc.(AVU0) | COMM | 00773U207 | $14.1M | 2,008,339 | 1.2% |
| Entrada Therapeutics Inc(TRDA) | COMM | 29384C108 | $9.3M | 584,955 | 0.8% |
| Vistagen Therapeutics Inc(VTGN) | COMM | 92840H400 | $8.1M | 2,676,580 | 0.7% |
| Tarsus Pharmaceuticals, Inc.(TARS) | COMM | 87650L103 | $7.6M | 231,820 | 0.6% |
| EyePoint Pharmaceuticals, Inc.(EYPT) | COMM | 30233G209 | $7.4M | 922,335 | 0.6% |
| Nektar Therapeutics(NKTREUR) | COMM | 640268108 | $5.2M | 4,000,000 | 0.4% |
| Aerovate Therapeutics Inc | COMM | 008064107 | $4.7M | 2,240,809 | 0.4% |
| Avalo Therapeutics Inc(AVTX) | COMM | 05338F306 | $4.6M | 483,000 | 0.4% |
| Kodiak Sciences Inc(KOD) | COMM | 50015M109 | $2.6M | 1,008,158 | 0.2% |
| An2 Therapeutics, Inc.(ANTX) | COMM | 037326105 | $1.7M | 1,555,118 | 0.1% |
| Ventyx Biosciences, Inc(VTYX) | COMM | 92332V107 | $689.3K | 316,195 | 0.1% |
| Cabaletta BIO, Inc(CABA) | COMM | 12674W109 | $409.7K | 86,795 | 0.0% |